Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standards for international trade.
Anthony FJ, Baker KB, Miller DJ, Young RC, Baird JH, Evans GR, Tyson JD, Scott A. Anthony FJ, et al. Among authors: baird jh. Vet Rec. 2004 Nov 20;155(21):683. Vet Rec. 2004. PMID: 15581148 No abstract available.
Supply of veterinary medicines.
Anthony FJ, Baker KB, Miller DJ, Young RC, Baird JH. Anthony FJ, et al. Among authors: baird jh. Vet Rec. 2003 May 17;152(20):635. Vet Rec. 2003. PMID: 12790174 No abstract available.
Antibiotic growth promoters.
Anthony FJ, Baker KB, Miller DJ, Young RC, Baird JH. Anthony FJ, et al. Among authors: baird jh. Vet Rec. 2003 Sep 27;153(13):408. Vet Rec. 2003. PMID: 14567671 No abstract available.
Animal health and welfare strategy.
Anthony FJ, Baker KB, Evans GR, Miller DJ, Scott A, Tyson JD, Young RC, Baird JH. Anthony FJ, et al. Among authors: baird jh. Vet Rec. 2004 Feb 14;154(7):215. Vet Rec. 2004. PMID: 14994869 No abstract available.
Cost sharing on animal health.
Scott A, Tyson D, Baker K, Young B, Anthony F, Baird J. Scott A, et al. Vet Rec. 2008 Mar 15;162(11):356. doi: 10.1136/vr.162.11.356. Vet Rec. 2008. PMID: 18344509 No abstract available.
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
Su YJ, Kramer AM, Hamilton MP, Agarwal N, Srinagesh HK, Baird JH, Sahaf B, Kuo A, Ehlinger ZJ, Desai MH, Rietberg SP, Tunuguntla R, Patel S, Chinnasamy H, Gkitsas-Long N, Klysz DD, Brown AK, Bharadwaj S, Dahiya S, Smith M, Muffly L, Mackall CL, Good Z, Feldman SA, Miklos DB, Frank MJ. Su YJ, et al. Among authors: baird jh. Cancer Discov. 2025 Jan 7. doi: 10.1158/2159-8290.CD-24-1071. Online ahead of print. Cancer Discov. 2025. PMID: 39775812
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Oak JS, Younes SF, Natkunam Y, Hamilton MP, Su YJ, Agarwal N, Chinnasamy H, Egeler E, Mavroukakis S, Feldman SA, Sahaf B, Mackall CL, Muffly L, Miklos DB; CARdinal-22 Investigator group. Frank MJ, et al. Among authors: baird jh. Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9. Lancet. 2024. PMID: 38996463 Free article. Clinical Trial.
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Othman T, et al. Among authors: baird jh. Br J Haematol. 2024 Jul;205(1):368-372. doi: 10.1111/bjh.19521. Epub 2024 May 26. Br J Haematol. 2024. PMID: 38797530 No abstract available.
41 results